The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
The company said it plans to use the funds to extend its commercial operations and develop new products broadly aimed at the life sciences research market.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The company has licensed the Limited Proteolysis technology developed by ETH Zurich Professor Paola Picotti, which can assess proteome-wide structural changes.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
The firm, which will open a Boston office at the end of Q1, did not disclose the amount raised but said it was in the "mid-single-digit millions" of dollars.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
